Group 1: Company Overview - Sichuan Zizhong Palace Pharmaceutical Co., Ltd. held an investor survey on November 2, 2021, attended by four institutions [2][3] - The survey was conducted in the company's conference room with key personnel including the Chairman and General Manager present [3] Group 2: Research and Development Plans - The company plans to increase R&D investment, focusing on the development of the original Chinese patent medicine "Qiu Liu Wei An Capsule" and secondary research on existing products like "Oriental Stomach Medicine Capsule" and "Qing Chang Tong Bian Capsule" [4] - Ongoing research projects include classic formulas such as "Er Dong Tang" and "Kai Xin San" [4] Group 3: Market Expansion Strategies - The company is exploring new marketing models for its unique Chinese patent medicines, including online sales and advertising on central channels [5] Group 4: Sales Performance - The sales revenue share of the main product, "Cerebrolysin Sodium Tablets," over the past three years is as follows: - 2018: 89.79% - 2019: 86.71% - 2020: 87.80% - First half of 2021: 90.54% [6] Group 5: Product Layout and Consistency Evaluation - Future product layout will focus on existing product lines, with chemical drugs targeting the nervous system and traditional Chinese medicine focusing on the digestive system [7] - The consistency evaluation for "Cerebrolysin Sodium Tablets" is currently in the pre-BE trial phase, with no other domestic companies having submitted applications for consistency evaluation as of the latest update [8]
梓橦宫(832566) - 关于接待机构投资者调研情况的公告